Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cybin Inc. N.CYBN

Alternate Symbol(s):  CYBN

Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders, all protected under its ever-growing IP portfolio.

The Market Herald Price Sensitive
{{currentVideo.title}} {{currentVideo.relativeTime}}
{{currentVideo.storiesTitle}}:
{{story.companySymbol}}
{{story.companySymbol}} {{story.headline}}
< Previous bulletin
Next bulletin >
View modes: 

Microdose Announces The 2nd Annual Microdose Awards

Miami, Florida--(Newsfile Corp. - August 9, 2022) - Microdose Psychedelic Insights, the leading guide to the business of psychedelics, is excited to announce the lineup of categories for the 2nd...read more

New Press Release - Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be...read article.

RooGold Reports High Grade Gold & Silver Assays from Preliminary Rock Chip Sampling Program

A total of 274 rock chip samples collected at the Arthurs Seat Project in the highly prospective New England Orogen in New South Wales, Australia to confirm the results of historical sampling. Field work was targeted at sampling mullock dumps and shafts at the Murray and Co mine and McDonalds Prospect, as well as sampling along the N-S fault and the greisen altered granite contact at the Arthurs Seat Prospect. ...read more

New Press Release - Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical

-- Expected to accelerate clinical development pathway of CYB004 for the potential treatment of anxiety disorders by nine months -- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today...read article.

New Press Release - Cybin Announces Additional Adelia Milestone Achievement

Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing Psychedelics to Therapeutics™, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved the milestone identified as...read article.

New Press Release - Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder

-- Marks the first novel psilocybin analog to enter clinical development -- -- Patient recruitment to commence immediately -- -- Pharmacokinetic and safety data readout expected in Q4 2022 -- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company...read article.

New Press Release - Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

- Company reiterates key pipeline and strategic milestones for 2022 – Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM”, today reported audited financial results for its fiscal year ended...read article.

RE:RE:Quiet Over Here. New Member needs Advice...

hi gajjardr, would you be able to explain why you feel so sure?  anything would be helpful, thanks. dug  rate and reply

RE:RE:Quiet Over Here. New Member needs Advice...

I just took a look at this company suggestion. Nice cheapie. Volume on all Shroom stocks has bottomed out only because people are awaiting the Health Canada studies. It's pretty obvious what will...read more

RE:Quiet Over Here. New Member needs Advice...

LOBE 100%  rate and reply

RE:Quiet Over Here. New Member needs Advice...

# Please type your reply above this line # If your request directly relates to a paid service such as Stockstream we will prioritize your matter and respond same business day between 6:00AM and 10:AM...read more

Quiet Over Here. New Member needs Advice...

What's a better value stock pick for mushrooms? LOBE or this one Cybin ???  rate and reply

check out $nirv

$nirv looks alot more attractive than cybin at the moment. not too mention the CEO is a legend. check them out...only been listed for 3 months  rate and reply

Excellent YT analysis on CYBN

https://youtu.be/9kFe_t-N4Ow  rate and reply

Solid Close Today....

And respectable volume. I expect the share price to remain strong going into next week with the upcoming Benzinga conference on psychedelics and CYBN CEO as keynote speaker. We shall see but I'm...read more

Cybin Successful Completion of In Vivo Preclinical Studies

March 29, 2022 08:00 AM Eastern Daylight Time TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on...read more

RE:RE:Forget CYBN - FSD Pharma has drug to cure MS

1. Fsd sued for misrepresentation to it's shareholders resulting in 5.5 mil settlement https://thedeepdive.ca/fsd-pharma-ends-class-action-lawsuit-with-5-5-million-settlement/ 2. Massive RS https:...read more

RE:Forget CYBN - FSD Pharma has drug to cure MS

Ignore this POS pumper for HUGE....he's a paid promoter who continuously posts paid PR for the company....and for him to claim that they have a cure for MS is beyond irresponsible and disgusting...read more

RE:RE:RE:RE:MILESTONES

Seems you were the one confused  rate and reply

RE:RE:RE:RE:RE:RE:RE:RE:MILESTONES

What did i tell you..GL  rate and reply

Awards Grant for Psychedelic Treatment Clinic

November 23, 2021 07:30 AM Eastern Standard Time TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on...read more